Effects of semax against the background of dopaminergic receptor blockade with haloperidol.
Sebentsova. E A EA; Levitskaya. N G NG; Andreeva. L A LA; Alfeeva. L Yu LY; Kamenskii. A A AA; Myasoedov. N F NF
Key Findings
- Semax at 0.05, 0.2, and 0.6 mg/kg did not improve haloperidol‑induced motor or exploratory deficits
- A low dose of semax (0.05 mg/kg) prevented haloperidol‑induced problems in active avoidance learning
- The protective effect was specific to a cognitive task, not general behavior
Practical Outcomes
- For biohackers, the data suggest semax might help protect certain learning or cognitive functions when dopamine signaling is blocked, but it doesn’t fix movement issues. The effect was only seen at a low dose in an animal model, so it’s not ready for everyday use or dosage recommendations yet.
Summary
In a rat study, giving semax through the nose didn’t change the movement problems caused by the dopamine blocker haloperidol, but a low dose (0.05 mg/kg) did stop the drug from messing up a learning test. Higher doses didn’t show this benefit.
Abstract
We studied the neurotropic effects of ACTH(4-10) analog semax against the background of dopaminergic receptors blockade with haloperidol. Intranasal administration of semax (0.05, 0.2, and 0.6 mg/kg) produced virtually no effect on disturbances of orientation and exploratory reactions and motor activity caused by intraperitoneal injection of 0.2 mg/kg haloperidol. By contrast, preliminary administration of 0.05 mg/kg semax prevented haloperidol-induced disturbances in active avoidance conditioning.
Study Information
pubmed
2006
2006-02-01T00:00:00.000Z
10.1007/s10517-006-0119-y
2
6